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Michael Sullivan, Bruce Morland, Piotr Czauderna, Giorgio Perilongo, for the International Childhood Liver Tumours Strategy Group (SIOPEL)*
Summary
Background The objective of this study was to establish the eﬃ  cacy and safety of a new treatment regimen consisting 
of dose-dense cisplatin-based chemotherapy and radical surgery in children with high-risk hepatoblastoma.
Methods SIOPEL-4 was a prospective single-arm feasibility study. Patients aged 18 years or younger with newly 
diagnosed hepatoblastoma with either metastatic disease, tumour in all liver segments, abdominal extrahepatic 
disease, major vascular invasion, low α fetoprotein, or tumour rupture were eligible. Treatment consisted of 
preoperative chemotherapy (cycles A1–A3: cisplatin 80 mg/m² per day intravenous in 24 h on day 1; cisplatin 70 mg/m² 
per day intravenous in 24 h on days 8, 15, 29, 36, 43, 57, and 64; and doxorubicin 30 mg/m² per day intravenous 
in 24 h on days 8, 9, 36, 37, 57, and 58) followed by surgical removal of all remaining tumour lesions if feasible 
(including liver transplantation and metastasectomy, if needed). Patients whose tumour remained unresectable 
received additional preoperative chemotherapy (cycle B: doxorubicin 25 mg/m² per day in 24 h on days 1–3 and 22–24, 
and carboplatin area under the curve [AUC] 10·6 mg/mL per min per day intravenous in 1 h on days 1 and 22) before 
surgery was attempted. After surgery, postoperative chemotherapy was given (cycle C: doxorubicin 20 mg/m² per day 
in 24 h on days 1, 2, 22, 23, 43, and 44, and carboplatin AUC 6·6 mg/mL per min per day in 1 h on days 1, 22, and 43) 
to patients who did not receive cycle B. The primary endpoint was the proportion of patients with complete remission 
at the end of treatment. Analysis was by intention to treat. This trial is registered at ClinicalTrials.gov, NCT00077389.
Findings We report the ﬁ nal analysis of the trial. 62 eligible patients (39 with lung metastases) were included and 
analysed. 60 (98%, 95% CI 91–100) of 61 evaluable patients (one child underwent primary hepatectomy) had a partial 
response to preoperative chemotherapy. Complete resection of all tumour lesions was achieved in 46 patients (74%). 
At the end of therapy, 49 (79%, 95% CI 67–88) of 62 patients were in complete remission. With a median follow-up 
of 52 months, 3-year event-free survival was 76% (95% CI 65–87) and 3-year overall survival was 83% (73–93). 60 (97%) 
patients had grade 3–4 haematological toxicity (anaemia, neutropenia, or thrombocytopenia) and 44 (71%) had at least 
one episode of febrile neutropenia. Other main grade 3 or 4 toxicities were documented infections (17 patients, 27%), 
anorexia (22, 35%), and mucositis (seven, 11%). One child died of fungal infection in neutropenia. Moderate-to-severe 
ototoxicity was documented in 31 (50%) patients. 18 serious adverse events (including two deaths) reﬂ ecting the 
observed side-eﬀ ects were reported in the trial (the most common was ototoxicity in ﬁ ve patients).
Interpretation The SIOPEL-4 treatment regimen is feasible and eﬃ  cacious for complete remission at the end of 
treatment for patients with high-risk hepatoblastoma.
Funding Cancer Research UK and Cancer Research Switzerland/Oncosuisse.
Introduction
Despite important progress in the cure of children with 
localised hepatoblastoma, the prognosis of patients with 
metastatic disease remains poor, with 5-year event-free 
survival of 21–28% and 5-year overall survival 
of 27–57%.1–14 Only the most recently published study of 
the International Childhood Liver Tumours Strategy 
Group (SIOPEL-3),15 which used intensive multiagent 
chemotherapy and aggressive surgery, managed to 
achieve a better outcome for these children (3-year event-
free survival 56%, 3-year overall survival 62%). To further 
improve the number of children cured with high risk, 
and in particular metastatic hepatoblastoma, new 
therapeutic approaches are needed that can increase 
treatment eﬃ  cacy without excessive toxicity.
Data from earlier studies suggest that cisplatin is the 
key chemotherapeutic drug in the treatment of hepato-
blastoma, but its optimum schedule and dose in this 
setting is not yet established. As shown in studies in 
adults, the modulation of dose density—the frequency 
of eﬀ ective drug dose administration—could be an 
important way to improve the antitumour eﬃ  cacy of 
cisplatin.16 Chemotherapy regimens based on the 
administration of weekly cisplatin have been eﬃ  cacious 
and feasible in diﬀ erent types of adult cancer without 
excessive severe toxicity.17–22 In view of the mild toxicity 
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of cisplatin in the previous SIOPEL trials, such a 
regimen could perhaps also be safe in children with 
hepatoblastoma.
On the basis of these data and considerations SIOPEL 
launched the present study to establish the eﬃ  cacy and 
safety of a new chemotherapy regimen based on dose-
dense (weekly) preoperative administration of cisplatin 
in combination with monthly doxorubicin and radical 
surgery in children with high-risk hepatoblastoma.
Methods
Study design and patients
SIOPEL-4 was an international, multicentre, prospective, 
single-arm feasibility trial to study the eﬃ  cacy and safety 
of an experimental treatment. The study was approved 
by local institutional review boards and undertaken in 
accordance with the principles of the Declaration of 
Helsinki and the rules of Good Clinical Practice. 
Informed written consent was obtained from all patients 
or parents.
The study was open to children with untreated high-
risk hepatoblastoma (age ≤18 years). Risk stratiﬁ cation 
was based on the results of previous SIOPEL studies. 
According to these results, high risk was deﬁ ned as 
tumour involving all four hepatic sections (PRE-
Treatment EXTent of disease [PRETEXT]-IV23,24), or 
presence of distant metastases, or tumour extension into 
the vena cava or all three hepatic veins, or into the main 
or both branches of the portal vein, or extrahepatic intra-
abdominal disease, or serum α fetoprotein (AFP) less 
than 100 μg/L at diagnosis, or tumour rupture. Patients 
with abnormal cardiac, renal, or liver function at 
diagnosis or known pre-existing hearing loss were 
excluded. Tumour extension was assessed by pre-
treatment imaging (ultrasound, CT, and MRI) according 
to the PRETEXT system.23,24 For the purposes of eligibility 
for this trial, pulmonary lesions were judged to be 
metastases if there was one nodule more than 10 mm or 
several nodules with at least one more than 5 mm. Biopsy 
and histological evaluation of the primary tumour was 
mandatory for all children.
Procedures
Treatment consisted of three cycles of preoperative 
chemotherapy (cycles A1–A3) followed by surgical removal 
of all remaining tumour lesions if feasible (including liver 
transplantation and metastasectomy if needed) followed 
by postoperative chemotherapy (cycle C). Patients whose 
tumour remained unresectable received additional 
chemotherapy (cycle B) before surgery was attempted. In 
these cases no postoperative chemotherapy was given 
(ﬁ gure 1). No additional therapy was recommended for 
microscopic residual disease after liver surgery.
Chemotherapy was given as follows: cisplatin, 
70 mg/m² per day intravenous infusion in 24 h on 
days 8, 15, 29, 36, 43, 57, and 64 in cycles A1–A3, 80 mg/m² 
per day in 24 h on day 1 in cycle A1; doxorubicin, 30 mg/m² 
per day intravenous infusion in 24 h on days 8, 9, 36, 37, 57, 
and 58 in cycles A1–A3, 25 mg/m² per day in 24 h 
on days 1, 2, 3, 22, 23, and 24 in cycle B, 20 mg/m² per day 
in 24 h on days 1, 2, 22, 23, 43, and 44 in cycle C; and 
carboplatin area under the curve (AUC) 10·6 mg/mL per 
min per day intravenous infusion in 1 h on days 1 and 22 in 
cycle B, AUC 6·6 mg/mL per min per day in 1 h on days 1, 
22, and 43 in cycle C. Cycle A3 was modiﬁ ed to avoid delay 
in surgery due to bone marrow toxicity of this course. 
Before starting a cycle patients should have recovered 
clinically from the previous course and must not have signs 
of active infection. Absolute neutrophil count should have 
recovered to higher than 1 × 10⁹ per L and platelet count to 
higher than 100 × 10⁹ per L. For infants and children with 
bodyweight less than 10 kg and in case of delay in chemo-
therapy because of toxicity, dose reduction was recom-
mended by the protocol (appendix). Delays in therapy due 
to toxicity were allowed according to protocol. To assist 
optimum treatment decisions by the treating centres, the 
protocol provided detailed guidelines for tumour 
assessment and surgery including the issue of diﬃ  cult or 
extreme resection, liver transplantation, and metas-
tasectomy (appendix). Details of post-transplant im muno-
suppressive regimen were not collected systematically.
The primary endpoint was the proportion of patients 
with complete remission at the end of trial treatment, 
Figure 1: Treatment design of the SIOPEL-4 study
C*=cisplatin 80 mg/m2 per day intravenous infusion in 24 h; on day 1 in cycle A1. C=cisplatin 70 mg/m² per day intravenous infusion in 24 h; on days 8, 15, 29, 36, 43, 57, 
and 64 in cycles A1–A3. D=doxorubicin 30 mg/m2 per day intravenous infusion in 24 h; on days 8, 9, 36, 37, 57, and 58 in cycles A1–A3. D*=doxorubicin 25 mg/m2 per day 
intravenous infusion in 24 h; on days 1, 2, 3, 22, 23, and 24 in cycle B. D**=doxorubicin 20 mg/m² per day intravenous infusion in 24 h; on days 1, 2, 22, 23, 43, and 44 in 
cycle C. CA*=carboplatin area under the curve (AUC) 10·6 mg/mL per min per day intravenous infusion in 1 h; on days 1 and 22 in cycle B. CA**=carboplatin AUC 6·6 mg/mL 
per min per day intravenous infusion in 1 h; on days 1, 22, and 43 in cycle C. Filled circle=assessment of response. Empty circle=assessment of response and resectability.
Surgery (including liver 
transplantation and 
metastectomy if needed)
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Cycle C 
Cycle B
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which is a good surrogate for event-free survival and was 
thought to be an adequate outcome measure for this 
trial. Secondary endpoints were the proportion of 
patients who responded to preoperative chemotherapy, 
the proportion of patients with complete resection, 
overall survival, and event-free survival. Tumour response 
and resectability were assessed by imaging and serum 
AFP concentration after each chemotherapy cycle 
according to the following criteria: complete response, 
deﬁ ned as no evidence of disease and normal AFP (for 
age); partial response, deﬁ ned as any tumour volume 
shrinkage and a decrease of AFP greater than 1 log below 
the original measurement; stable disease, deﬁ ned as no 
tumour volume change and no change or less than 1 log 
fall of AFP; progressive disease, deﬁ ned as unequivocal 
increase of tumour size in one or more dimensions or 
any unequivocal increase of the AFP concentration, or 
both; complete surgical resection, deﬁ ned as total 
macroscopic removal of all tumour lesions; and complete 
remission, deﬁ ned as no evidence of tumour on imaging 
and normal (for age) serum AFP. Overall tumour 
response to chemotherapy was evaluated at the end of 
preoperative chemotherapy.
Acute toxicity was evaluated after each chemotherapy 
cycle. Evaluation of cardiac toxicity and ototoxicity was 
also required during follow-up. Establishment of normal 
baseline cardiac, renal, liver, and audiological functions 
were required before the start of treatment. Toxicity was 
graded according to the National Cancer Institute 
Common Toxicity Criteria for Adverse Events version 3.0 
and the Brock grading for ototoxicity.25
The trial was monitored for excessive toxicity by regular 
evaluation of severe adverse event reports and toxicity data. 
These data were reported to an independent data 
monitoring committee that assessed and judged observed 
toxicity at least once a year and made recommendations 
for amendments or closing of the study if necessary. 
Statistical analysis
We used Simon’s two-stage optimal design with a 
probability of complete remission in 60% of patients or 
less (from the SIOPEL-3HR study) as the null hypothesis 
and a probability of 80% of patients or higher as the 
alternative hypothesis. The sample size was determined 
by testing of the null versus the alternative hypothesis at 
a signiﬁ cance level of 0·05 and a power of 90%. The 
sample size was n1=19 for stage 1 and n2=34 for stage 2, 
resulting in a maximum sample size of 53 if the trial 
was not stopped after stage 1 analysis. The stage 1 
evaluation was done on the ﬁ rst 19 treated patients in 
February, 2007, and concluded that early stopping 
criteria were not met and the trial could be continued. 
The alternative hypothesis was to be accepted if the 
number of patients with complete remission was 38 or 
higher. A stopping rule for safety was devised on the 
basis of the number of patients in whom possible 
treatment-related severe adverse events developed, 
including death and grade 4 toxic eﬀ ects. SAS version 9.1 
was used for all analyses.
Role of the funding source
The funding sources had no role in the design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Figure 2: Enrolment, treatment, and outcome of patients
*Withdrawn after second preoperative chemotherapy cycle (A2) because of 
grade 3 ototoxicity. †One toxic death, one death due to tumour rupture. 
‡Withdrawn after third preoperative chemotherapy cycle (A3) with partial 
response. §Unresectable because of multiple lung lesions, no surgery attempted.
67 patients enrolled
5 misdiagnosis
62 eligible
1 stable disease after preoperative chemotherapy,
    withdrawn before surgery*
60 complete or partial response after 
       preoperative chemotherapy
46 complete surgical resection of all 
       remaining lesions after 
       preoperative chemotherapy
4 no complete remission
1 primary surgery
2 death before surgery†
1 withdrawn before surgery‡
1 no documentation of surgery
2 surgical death
6 liver resection in the presence of residual lung 
    lesions (small lesions), no metastasectomy
1 liver resection in the presence of residual lung 
    lesions (unresectable), no metastasectomy
49 in complete remission at the end 
       of treatment
1 unresectable disease§
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Results
Between Jan 1, 2005, and Aug 31, 2009, 67 patients were 
enrolled in the trial from 18 countries worldwide (ﬁ gure 2). 
Five patients were excluded from the analysis because of 
misdiagnosis after central pathology review of the biopsy 
material (four hepatocellular carcinomas, one rhabdoid 
tumour). Table 1 shows the clinical characteristics of the 
remaining 62 eligible patients. No children were excluded 
because of abnormal cardiac, renal, or liver function or 
pre-existing hearing loss.
Table 1 shows the number of chemotherapy cycles given 
in total and per patient. In 50 (81%) patients all four cycles 
were given and documented. Six patients received fewer 
than the prescribed four cycles because of death during 
therapy (four patients) or withdrawal (two). In six patients 
postoperative chemotherapy was not documented. The 
cumulative delay in the administration of the second and 
third cycles of preoperative therapy (A2 and A3) because of 
toxicity ranged from –4 to 63 days (median 7 days, mean 
10 days); reasons for early start of the next cycle of 
chemotherapy in some patients were good haematological 
recovery and clinical condition. Dose reduction was applied 
in four of the 61 second cycles (A2), seven of the 59 third 
cycles (A3), and eight of the 37 postoperative (C) cycles all 
because of previous haematological toxicity (no dose 
Patients (n=62)
Age
Median (months) 19·1 (2·6–15·9)
0 to <12 months 14 (23%)
1 to <3 years 32 (52%)
≥3 years 16 (26%)
Sex
Female 23 (37%)
Male 39 (63%)
AFP
Median (μg/L) 297 768·0 (42·0–3 315 400·0)
<100 μg/L 2 (3%)
Tumour extension according to PRETEXT system
PRETEXT I 2 (3%)
PRETEXT II 17 (27%)
PRETEXT III 27 (44%)
PRETEXT IV 16 (26%)
Lung metastases* 39 (63%)
Vascular invasion 24 (39%)
Abdominal extrahepatic disease† 6 (10%)
Tumour rupture at diagnosis 10 (16%)
SCUD histology‡ 5 (8%)
Multifocal primary tumour 20 (32%)
Chemotherapy cycles administered
Cycle A1 62 (100%)
Cycle A2 61 (98%)
Cycle A3 59 (95%)
Cycle B 13 (21%)
Cycle C 37 (60%)
Number of cycles received by patient
1 cycle (A1) 1 (2%)
2 cycles (A1+A2) 2 (3%)
3 cycles (A1+A2+A3) 9 (15%)
4 cycles (A1–A3+B or C) 50 (81%)
 Data are n (%) or median (range). AFP=serum α fetoprotein. PRETEXT=PRE-
Treatment EXTent of disease.23,24 SCUD=small cell undiﬀ erentiated hepato blastoma. 
*Multiple lesions in 38, single lesion in one patient. †Established on imaging, not 
conﬁ rmed by histology. ‡Established locally in two (no review available), locally and 
in central review in two, and in central review only in one patient.
Table 1: Patient characteristics at diagnosis and chemotherapy cycles given Figure 3: Kaplan-Meier estimates of (A) event-free and (B) overall survival for the whole study population
Dotted lines show 95% CIs.
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reductions were observed in the additional preoperative [B] 
cycle). Two patients who withdrew from the study received 
some non-protocol chemotherapy after withdrawal.
60 (98%, 95% CI 91–100) of 61 evaluable patients (one 
child underwent primary hepatectomy) had a partial 
response to preoperative chemotherapy. The remaining 
patient had a decrease in tumour volume and a decrease in 
AFP less than 1 log and was classiﬁ ed as having stable 
disease. This patient later achieved complete remission 
and has been cured. In most patients, partial response was 
reached early during preoperative treatment. No patients 
could achieve complete response because the evaluation 
was done before surgery. In the 13 patients who received 
additional preoperative chemotherapy (cycle B), the overall 
response status was not changed. However, one patient 
who had partial response in the lungs after cycles A1–A3 
had a complete response of the lung lesions after additional 
preoperative chemotherapy. Of the 39 patients with initial 
lung metastases, a complete response of the lung lesions 
was achieved in 20 patients and partial response 
in 18 patients, with preoperative chemotherapy alone (97% 
patients responded). In one patient no evaluation of the 
lung lesions was done.
In 53 (85%) of the 62 patients, complete macroscopic 
resection of the primary tumour was achieved with partial 
hepatectomy (n=37) or liver transplantation (n=16). Two 
children died of postoperative complications. In ﬁ ve 
patients, no surgery was attempted because of unresectable 
disease (one patient), early death (two), or withdrawal 
before surgery (two). One patient underwent primary 
surgery because of tumour rupture, and for one patient 
data were missing. Microscopic residuals were seen in ﬁ ve 
of the 37 patients who underwent partial hepatectomy. All 
achieved complete remission and none relapsed.
Of the 53 patients with complete resection of the 
primary tumour, seven also underwent pulmonary 
metastasectomy. Complete resection of all tumour 
lesions was achieved in 46 patients (74%, 95% CI 62–84). 
In seven patients with residual lung lesions after 
chemotherapy, the liver tumour was resected but no 
metastasectomy was done (ﬁ gure 2).
16 patients were transplanted, eight with PRETEXT-IV, 
ﬁ ve with PRETEXT-III, and three with PRETEXT-II 
tumour. Seven of these patients had initial metastases, 
which were cleared with chemotherapy in six patients. In 
one patient, metastasectomy was done with no viable 
tumour cells in the specimen. None of these seven 
patients had a (pulmonary) relapse.
Of the 46 patients with complete resection of all tumour 
lesions, one developed recurrent lung lesions before the 
end of treatment. In three patients, AFP remained raised. 
Conversely, six patients with small residual pulmonary 
lesions after liver surgery who did not undergo metas-
tasectomy achieved complete remission with postsurgical 
chemotherapy given according to protocol. In 
total 49 (79%, 95% CI 67–88) of 62 patients were in complete 
remission at the end of therapy, including the one who 
underwent primary hepatectomy, close to the prespeciﬁ ed 
goal of 80%. Six patients were alive with evidence of disease 
(three with tumour visible on imaging studies, three with 
slightly raised AFP), four died (one of tumour bleeding, 
one of toxicity, two of postoperative compl ications), two 
were withdrawn (one after two cycles with stable disease for 
grade 3 ototoxicity; one after cycles A1–A3 in partial 
response), and one was not documented (ﬁ gure 2).
Median follow-up for surviving patients was 52 (range 
3–83, IQR 27·9) months. At last follow-up 15 events were 
registered: ﬁ ve relapses, six progressions from residual 
disease, and four deaths for other reasons. 12 patients died 
of either tumour progression or relapse (eight), toxicity 
Reported toxicity in cycles A1–A3 Number of patients 
with reported toxicity 
in cycle B
Number of patients 
with reported toxicity 
in cycle C
Number of patients Number of cycles
Haemoglobin
Grade 1 6 (10%) 8 (4%) ·· 1 (3%)
Grade 2 27 (44%) 40 (22%) 3 (23%) 7 (19%)
Grade 3 53 (85%) 105 (58%) 7 (54%) 18 (49%)
Grade 4 11 (18%) 12 (7%) 2 (15%) 6 (16%)
Neutrophils
Grade 1 2 (3%) 3 (2%) ·· 1 (3%)
Grade 2 6 (10%) 7 (4%) ·· 2 (5%)
Grade 3 20 (32%) 27 (15%) ·· 5 (14%)
Grade 4 53 (85%) 105 (58%) 12 (92%) 25 (68%)
Platelets
Grade 1 21 (34%) 25 (14%) 1 (8%) 3 (8%)
Grade 2 9 (15%) 9 (5%) ·· 2 (5%)
Grade 3 29 (47%) 38 (21%) 2 (15%) 6 (16%)
Grade 4 39 (63%) 66 (36%) 9 (69%) 19 (51%)
Febrile neutropenia
Grade 1 1 (2%) 1 (1%) ·· 1 (3%)
Grade 2 2 (3%) 4 (2%) ·· 1 (3%)
Grade 3 41 (66%) 7 (4%) 8 (62%) 16 (43%)
Grade 4 3 (5%) 3 (2%) ·· 2 (5%)
Infection (documented)
Grade 2 7 (11%) 8 (4%) 1 (8%) ··
Grade 3 17 (27%) 18 (10%) 2 (15%) 5 (14%)
Grade 4 ·· ·· ·· 1 (3%)
Fever
Grade 1 15 (24%) 19 (10%) 1 (8%) 3 (8%)
Grade 2 13 (21%) 15 (8%) 1 (8%) 1 (3%)
Grade 3 2 (3%) 3 (2%) ·· ··
Vomiting
Grade 1 20 (32%) 21 (12%) 1 (8%) 3 (8%)
Grade 2 29 (47%) 46 (25%) 1 (8%) 5 (14%)
Grade 3 4 (6%) 4 (2%) ·· 1 (3%)
Anorexia
Grade 1 11 (18%) 12 (7%) 2 (15%) 3 (8%)
Grade 2 10 (16%) 12 (7%) 2 (15%) 3 (8%)
Grade 3 22 (35%) 36 (20%) 2 (15%) 5 (14%)
(Continues on next page)
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(one, fungal infection in profound neutropenia), surgical 
compli cations (two, one intra operative bleeding and shock; 
one, lethal postoperative wound infection), or tumour 
bleeding (one, spontaneous intratumour bleeding with 
irreversible haemorrhagic shock before the second cycle of 
chemo therapy). The Kaplan-Meier estimate of 3-year event-
free survival was 76% (95% CI 65–87) and of overall survival 
was 83% (95% CI 73–93) for the whole group (ﬁ gure 3). 
The relapses occurred 5–48 months after the end of 
treatment at the following sites: locoregional (three), lungs 
(one), unknown (one). Of the ﬁ ve patients, two had initial 
metastases, two PRETEXT-IV tumours, and three initial 
tumour rupture. Two of the ﬁ ve patients died of their 
cancer, the other three had a second complete remission.
19 of the 20 patients with metastatic disease with com-
plete response in the lungs were in complete remission at 
the end of treatment. In one patient lung lesions recurred 
before the ﬁ nal evaluation. Of the 18 patients with partial 
response, seven underwent metastasectomy (six complete, 
one incomplete but no viable tumour). Four of these seven 
had a complete remission. In the other three patients no 
visible tumour was detected, but AFP was still raised at 
the end of therapy. Six of the 18 patients had some residual 
lesions in the lungs at the end of preoperative chemo-
therapy but did not undergo pul monary metastasectomy. 
All achieved complete remission with further chemo-
therapy per protocol. In one of these patients, lung disease 
recurred 5 months after the end of therapy. In two of 
the 18 children the lung lesions remained unresectable; in 
one the liver tumour was resected but no metastasectomy 
was done, and in the other no surgery was attempted. 
Three of the 18 children died before surgery.
27 (69%) of 39 patients with metastatic disease had 
complete resection of all tumour lesions. 29 patients (74%) 
were in complete remission at the end of therapy. Of the 
remaining ten patients, six did not achieve complete 
remission because of residual pulmonary disease: in one 
patient lung lesions disappeared with preoperative chemo-
therapy but recurred after liver surgery; in two patients 
pulmonary lesions were diminished, but remained 
unresectable; and in three patients no visible tumour was 
left, but AFP remained slightly raised at the end of 
treatment. Two of these six patients had low initial AFP and 
small cell undiﬀ erentiated (SCUD) tumour. 3-year event-
free survival was 77% (95% CI 63–90) and 3-year overall 
survival was 79% (95% CI 66–92) for the 39 patients with 
metastasis. In an exploratory analysis, 27 (78%) of 
37 patients with metastatic disease and AFP higher 
than 100 μg/L had achieved continuous complete remission 
at the end of therapy. 
In 11 of the 16 patients with initial PRETEXT-IV tumour, 
chemotherapy led to downstaging of the liver mass to 
category III in six, category II in four, and category I in 
one patient as assessed preoperatively. In four patients 
the tumour extent remained category IV (information 
was missing for one patient). In four children the tumour 
was resected with partial hepatectomy, and eight patients 
underwent liver transplantation. Pulmonary metas-
tasectomy was done in one patient. Complete resection of 
all tumour lesions was achieved in 12 patients (75%). One 
patient died of postoperative complications, in one no 
Reported toxicity in cycles A1–A3 Number of patients 
with reported toxicity 
in cycle B
Number of patients 
with reported toxicity 
in cycle C
Number of patients Number of cycles
(Continued from previous page)
Mucositis
Grade 1 13 (21%) 16 (9%) 1 (8%) 3 (8%)
Grade 2 7 (11%) 9 (5%) 3 (23%) 1 (3%)
Grade 3 7 (11%) 11 (6%) 1 (8%) ··
Diarrhoea
Grade 3 2 (3%) 2 (1%) ·· 2 (5%)
Hypertension
Grade 4 1 (2%) 1 (1%) ·· ··
Haemorrhage or bleeding
Grade 4 1 (2%) 1 (1%) 1 (8%) ··
Allergy
Grade 3 1 (2%) 1 (1%) ·· ··
Left ventricular systolic dysfunction
Grade 3 1 (2%) 1 (1%) ·· ··
Glomerular ﬁ ltration rate
Grade 1 7 (11%) 7 (4%) ·· 3 (8%)
Grade 2 2 (3%) 2 (1%) 1 (8%) 2 (5%)
Grade 3 1 (2%) 1 (1%)
Aspartate aminotransferase
Grade 1 31 (50%) 47 (26%) 3 (23%) 9 (24%)
Grade 2 13 (21%) 13 (7%) ·· 2 (5%)
Grade 3 7 (11%) 7 (4%) ·· 2 (5%)
Grade 4 1 (2%) 1 (1%)
Alanine aminotransferase
Grade 1 25 (40%) 36 (20%) 2 (15%) 7 (19%)
Grade 2 6 (10%) 6 (3%) 1 (8%) 2 (5%)
Grade 3 5 (8%) 5 (3%) ·· 3 (8%)
Grade 4 ·· 1 (3%)
Hypomagnesaemia
Grade 1 23 (37%) 34 (19%) 2 (15%) 5 (14%)
Grade 2 10 (16%) 16 (9%) ·· 1 (3%)
Grade 3 4 (6%) 4 (2%) ·· 1 (3%)
Hypophosphataemia
Grade 3 2 (3%) 2 (1%) ·· ··
Grade 4 1 (2%)
Hypokalaemia
Grade 4 1 (2%) ·· ·· ··
Hyperbilirubinaemia
Grade 1 11 (18%) 11 (6%) ·· 2 (5%)
Grade 2 2 (3%) 2 (1%) ·· 2 (5%)
Grade 3 3 (5%) 3 (2%) ·· ··
Data are n (%). Cycles A1–A3 were given to 62 patients (in total 182 cycles), additional preoperative chemotherapy 
(cycle B) to 13 patients, and postoperative chemotherapy (cycle C) to 37 patients. 
Table 2: Short-term toxicity in the SIOPEL-4 trial
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surgery was attempted because of unresectable lung 
disease, and two patients were withdrawn before surgery. 
All 12 children with complete tumour resection had 
complete remission. 3-year event-free survival was 73% 
(95% CI 51–96) and overall survival was 80% (95% CI 
60–100) for the 16 patients with PRETEXT-IV tumours, 
including the seven with lung metastases. Of the nine 
patients who did not have metastatic disease at diagnosis, 
eight (89%) had a complete resection and eight (89%) 
achieved complete remission.
60 (97%) patients had grade 3–4 haematological toxicity 
after at least one of the cycles. The highest frequency of 
neutropenia and thrombocytopenia was after additional 
preoperative chemotherapy (cycle B; 12 [92%] and 11 [85%], 
respectively), which was given only to 13 patients. 44 (71%) 
patients had at least one episode of febrile neutropenia. 
Grade 3–4 infection or mucositis aﬀ ected only a few 
patients. Table 2 lists all reported short-term toxicity 
(other than ototoxicity). One patient died of fungal 
infection in profound neutropenia.
Of the 61 children who received at least two preoperative 
cycles, ototoxicity was evaluated and documented in 54, 
with at least two measurements, both done after at least 
two cycles or during follow-up. The number and percentage 
of patients with ototoxicity according to the Brock criteria 
were: grade 0: 18 (30%), grade 1: ﬁ ve (8%), grade 2: 15 (25%), 
grade 3: 12 (20%), grade 4: four (7%). In seven patients 
(10%) ototoxicity was not suﬃ  ciently documented.
18 serious adverse events, including two deaths, were 
reported (appendix). The most common serious adverse 
event was ototoxicity in ﬁ ve patients. One child was 
withdrawn by the local physician after two cycles (A1+A2) 
because of Brock grade 3 ototoxicity. On the basis of the 
observed toxicity, the independent data monitoring 
committee did not recommend any changes or amend-
ment to the protocol during the trial.
Discussion
The SIOPEL-4 trial addressed the question of whether 
increased dose density of cisplatin in the preoperative 
phase can improve the prognosis of children with high-
risk, in particular metastatic, hepatoblastoma (panel). Our 
results provide ﬁ rm evidence for the eﬃ  cacy of the applied 
regimen, with close to 80% of patients achieving complete 
remission at the end of treatment. The proportion of 
patients with complete remission and the 3-year event-
free and overall survival compare favourably with results 
of previous studies and suggest an improvement in the 
prognosis of children with high-risk hepatoblastoma.
In view of the rarity of high-risk hepatoblastoma, 
a randomised controlled study to directly prove the superi-
ority of the study treatment was not deemed feasible within 
an acceptable timeframe. Instead, a single-arm study was 
designed with complete remission at the end of trial 
treatment as the primary endpoint, which is an objective 
and relevant outcome measure and allows analysis shortly 
after the study is closed. The eﬃ  cacy of this regimen was 
primarily compared with the results of SIOPEL-3HR, the 
previous high-risk study of the SIOPEL group. SIOPEL-4 
aimed to achieve an improvement in proportion of patients 
with complete remission of 20% or more (from ≤60% [in 
SIOPEL-3HR] to ≥80%), which is regarded as a clinically 
relevant and signiﬁ cant improvement.
Since tumour-free status at the end of treatment is a 
prerequisite for cure and the relapse rate in high-risk 
hepatoblastoma is low, complete remission is thought to 
be a good surrogate for overall and event-free survival. 
Additionally, to produce robust survival data that can be 
adequately compared with previously published results, 
patients were followed up for a median of 52 months 
(table 3). Data from previous studies suggest that almost 
all relapses after hepatoblastoma treatment occur in the 
ﬁ rst 2 years after the end of treatment. On the basis of 
these data the current follow-up seems largely suﬃ  cient 
for a good estimate of the long-term eﬃ  cacy of the 
regimen and gives a good basis for comparison with 
other studies.
Although we acknowledge that comparison with 
historical controls does not provide the highest level of 
evidence, we are convinced that in this context the use of 
historical controls is the best available option to indicate 
improvement. We believe that the high similarities in 
patient populations, inclusion and exclusion criteria, and 
trial design, conduct, and analysis make the comparison 
with previous SIOPEL studies appropriate.
Panel: Research in context
Systematic review
We searched PubMed on Jan 20, 2004, for clinical trials published in English before 
Jan 1, 2004, using the keywords “hepatoblastoma”, ”metastatic”, or “high risk”, or “locally 
advanced or “unresectable hepatoblastoma” and identiﬁ ed 11 articles that provided 
prospective survival data for at least one of these patient groups. No randomised trials 
were found in these speciﬁ c subgroups. The results showed 5-year event-free survival of 
21–28% and 5-year overall survival of 27–57% in patients with metastatic 
hepatoblastoma. Published 5-year event-free survival was 48% and overall survival was 
53% for patients with high-risk hepatoblastoma. When preparing the report we did a 
further PubMed search on Oct 1, 2012, using the same search terms and conditions. Four 
more relevant articles were identiﬁ ed, one of which showed improved results—compared 
with the previous data—in high-risk hepatoblastoma (3 year event-free survival 65%, 
overall survival 69%; 56% and 62% for the metastatic subgroup). We cited the most 
relevant articles in this Article. Systematic search for publications on the use of “(high) 
dose-dense” or “weekly” cisplatin in childhood cancer retrieved no articles.
Interpretation
Our study used a novel and unique design of dose-dense (weekly) cisplatin in the 
treatment of patients with high-risk hepatoblastoma and provides ﬁ rm evidence for the 
feasibility and eﬃ  cacy of this approach. To our knowledge, our paper is the ﬁ rst report on 
the use of dose-dense cisplatin in the treatment of paediatric patients with cancer. The 
reported outcome, in particular for those with metastatic disease, is higher than ever 
before achieved for children with high-risk hepatoblastoma and denotes an important 
improvement in the prognosis of these children. Although further evaluation of the 
long-term toxicity is needed, the presented treatment strategy could be now regarded as 
ﬁ rst choice in the treatment of patients with metastatic or very high-risk hepatoblastoma.
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The most important progress has been achieved in the 
cure of children with metastases. All evaluable patients 
showed a remarkable response to chemotherapy and in 
more than half, the lung lesions were entirely cleared. The 
complete response in the lungs achieved in this way 
appears stable, since 19 (95%) of the 20 patients remained 
in continuous complete remission, including the six who 
underwent liver transplantation. 25 of the 39 patients had 
complete remission without pulmonary surgery and two 
additional patients had no viable tumour cells in their 
metastasectomy specimens, emphasising the eﬃ  cacy of 
the applied chemotherapy. The low number of patients 
who had lung relapse (one, 5%) also shows the stability of 
the lung responses achieved in this way. Additionally, two 
of the six children who did not have complete remission 
because of pulmonary disease had low initial AFP and 
SCUD histology, both features known as bad prognostic 
factors.26,27 The outcome of patients with metastatic disease 
achieved in this study appears to be better than the results 
of all previously published studies, including SIOPEL-
3HR, and denotes a major improvement in the cure of 
these children (table 3).
The excellent response of lung metastases to pre-
operative chemotherapy in this study is in line with the 
promising results of the previous SIOPEL study (3HR), 
which seem to be further improved by the highly eﬀ ective 
SIOPEL-4 regimen. Our results emphasise the importance 
of chemotherapy responsiveness of lung metastases and 
the role of chemotherapy in the cure of these patients. 
Surgery remains important in patients whose lung lesions 
are not cleared by chemotherapy alone.
The presented results for patients with PRETEXT-IV 
tumour conﬁ rm the fairly good prognosis of this subgroup 
and might suggest a slight improvement in overall survival 
compared with previous SIOPEL studies (table 3). Our 
data underline the importance of both chemotherapy and 
liver transplantation in the management of these tumours. 
Because of an excellent response to chemotherapy, the 
tumour extent decreased signiﬁ cantly in most patients and 
partial hepatectomy became feasible in four children who 
otherwise would have needed liver transplantation. This 
study conﬁ rms that transplantation is a safe and potentially 
curative option for patients whose primary tumour 
remains unresectable with partial hepatectomy.28–30 These 
results also emphasise that the presence of lung metastases 
at diagnosis is not a contraindication to liver trans-
plantation, provided that eﬀ ective preoperative chemo-
therapy is given, the lung lesions respond to chemotherapy, 
and are completely cleared before transplantation by 
chemotherapy and metastasectomy (if needed).
We believe that the most important explanation for the 
improved results is the increased preoperative dose 
density of cisplatin used in this treatment regimen 
(47·5 mg/m² per week vs 22·9 mg/m² per week in 
SIOPEL-3HR), in the context of the previously established 
multidisciplinary approach. To our knowledge this study 
is the ﬁ rst time this approach has been applied in a 
paediatric treatment protocol. Our results encourage 
exploration of the role of dose-dense cisplatin-based 
regimens in the treatment of other paediatric tumours.
As expected, the main toxicity was haematological, 
leading to profound neutropenia in most children. 
Extensive experience in management of chemotherapy-
related side-eﬀ ects, neutropenia, infections, bleeding, 
and adequate supportive treatment, including the 
possibility of intensive care support, are therefore needed 
Stage Number of 
patients
Patients who responded 
to treatment (95% CI)
Patients who underwent 
complete resection (95% CI)
Event-free or progression-free 
survival
Overall survival
All patients with high-risk hepatoblastoma
SIOPEL-4 High risk 62 98% (91–100) 74% (62–84) 3-year 76% (95% CI 65–87) 3-year 83% (95% CI 73–93)
SIOPEL-315 High risk 151 79% (71–85) 70% (62–77) 3-year 65% (95% CI 57–73) 3-year 69% (95% CI 62–77)
SIOPEL-23 High risk 58 78% (65–87) 67% (54–79) 3-year 48% (SE 13) 3-year 53% (SE 13)
Patients with distant metastases at diagnosis
SIOPEL- 4 Metastatic 39 97% 70% 3-year 77% (95% CI 63–90) 3-year 79% (95% CI 66–92)
SIOPEL-315 Metastatic 70 71% ·· 3-year 56% (95% CI 44–68) 3-year 62% (95% CI 50–73)
SIOPEL-23 Metastatic 25 72% 60% ·· 3-year 44%
SIOPEL-11,2 Metastatic 31 84% ·· 5-year 28% (95% CI 12–44) 5-year 57% (95% CI 39–75)
INT-009810 Metastatic 40 ·· ·· 5-year 25% (SE 7) 5-year 37% (SE 8)
POG-934511 Metastatic 11 ·· 36% 5-year 27% (SE 16) 5-year 27% (SE 16)
JPLT-214 Metastatic 35 ·· ·· 5-year 21% 5-year 44%
Patients with PRETEXT-IV tumour at diagnosis
SIOPEL-4 PRETEXT IV (no metastases)* 9 89% 89% 3-year 75% 3-year 88%
SIOPEL-315 PRETEXT IV (no metastases)* 49 94% 88% 3-year 75% 3-year 77%
SIOPEL-23 PRETEXT IV (no metastases)* 21 81% 76% ·· 3-year 61%
PRETEXT=PRE-Treatment EXTent of disease.23,24 *Patients with α fetoprotein less than 100 μg/L or metastasis were excluded.
Table 3: Response and outcome results of SIOPEL-4 compared with previous studies 
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when this protocol is used. Despite the increased dose 
density of cisplatin, no serious renal toxicity has been 
observed. The incidence and severity of documented 
ototoxicity seems acceptable in view of the previously 
unsatisfactory prognosis. However, because of the young 
age of most patients, follow-up audiology investigations 
will be needed to establish the incidence and severity of 
long-term ototoxicity after this regimen.
In conclusion, the SIOPEL-4 treatment regimen with 
dose-dense administration of cisplatin and radical 
surgery is a feasible and eﬀ ective treatment and improves 
the prognosis of children with high-risk hepatoblastoma, 
in particular of those with metastatic disease.
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